iShares US Pharmaceuticals ETF
87 hedge funds and large institutions have $259M invested in iShares US Pharmaceuticals ETF in 2014 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 8 closing their positions.
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
1% more funds holding
Funds holding: 86 → 87 (+1)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less capital inflows, than outflows
Capital inflows: $25.7M | Capital outflows: $29.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$6.2M |
| 2 |
Virtu KCG Holdings
New York
|
+$2.82M |
| 3 |
Pinnacle Advisory Group
Columbia,
Maryland
|
+$2.07M |
| 4 |
Goldman Sachs
New York
|
+$1.97M |
| 5 |
Advisors Preferred
Rockville,
Maryland
|
+$1.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
-$7.92M |
| 2 |
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$7.22M |
| 3 |
Tower Research Capital (TRC)
New York
|
-$3.76M |
| 4 |
SCP
Syntal Capital Partners
Midland,
Texas
|
-$2.25M |
| 5 |
Morgan Stanley
New York
|
-$1.86M |
IHE Hedge Fund Activity: Q2 2014 in Review
87 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q2 2014, worth a combined $259M — up 5.1% from $247M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new IHE positions and 8 closed out — a net gain of 1 holder — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Bank of America, adding an estimated $6.2M. The largest seller was Clark Capital Management Group, exiting entirely with an estimated $7.92M sold.
- 87 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q2 2014, up from 86 in Q1 2014.
- Funds reported $259M of iShares US Pharmaceuticals ETF stock for Q2 2014, up 5.1% quarter-over-quarter.
- 9 funds opened new iShares US Pharmaceuticals ETF positions in Q2 2014 and 8 closed out, a net change of +1 holder.
- The largest iShares US Pharmaceuticals ETF buyer in Q2 2014 was Bank of America, an estimated $6.2M added.
- The largest iShares US Pharmaceuticals ETF seller in Q2 2014 was Clark Capital Management Group, an estimated $7.92M sold.
Based on aggregated 13F filings for Q2 2014.